Health CarePharmaceuticals and Biotechnology
  • Price (CHF)0.1272
  • Today's Change-0.003 / -2.15%
  • Shares traded14.21k
  • 1 Year change-87.53%
  • Beta1.7073
Data delayed at least 15 minutes, as of Dec 06 2022 16:12 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

  • Revenue in CHF (TTM)1.25m
  • Net income in CHF-21.42m
  • Incorporated2007
  • Employees28.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lysogene SA9.15m-7.29m11.30m23.00------1.24-0.436-0.4360.5386-0.16050.4568----402,087.00-36.43-40.97-81.82-126.32-54.94-94.68-79.75-151.78---38.441.29---72.09---167.31--134.89--
Kolinpharma SpA11.67m232.53k11.35m110.0048.811.428.440.97250.14340.14347.204.910.64963.962.62111,340.201.293.881.786.0956.2150.401.995.261.922.830.4079--36.2034.87-0.8406--6.18--
Scandion Oncology A/S-9.05bn-9.05bn11.42m----1.01----------3.08----------------------------0.0072-------217.81------
AroCell AB (publ)2.75m-5.62m11.46m----0.530--4.17-0.3854-0.38540.1641.040.12244.768.63---25.27-32.88-26.58-35.44-15.37-37.34-206.39-966.137.41-20,923.000.00--14,180.95194.00-107.99---47.95--
Genflow Biosciences PLC-114.89bn-114.89bn11.76m----3.57----------0.0098----------------------------0.00--------------
Bivictrix Therapeutics PLC0.00-3.71m11.77m5.00--2.03-----0.0547-0.05470.000.07640.00----0.00-100.73---120.22-------------4.320.0464-------450.59------
Nordic Nanovector ASA0.00-41.13m11.94m40.00--0.6903-----4.20-,940.80----0.00-------5.81---29.60--
Genincode PLC1.40m-6.27m12.38m20.00--0.9606--8.85-0.057-0.0570.01270.11710.165630.143.3160,910.50-74.24---82.03--45.64---448.21--15.89--0.00--20.11---255.23------
Fusion Antibodies PLC5.51m-1.38m12.40m53.00--2.93--2.25-0.0463-0.04630.1850.14160.89334.383.2590,547.17-22.34-23.43-28.10-27.3851.3948.22-25.01-38.133.06-165.630.0184--15.2220.1858.61--23.37--
Addex Therapeutics Ltd1.25m-21.42m12.73m28.00--0.8691--10.20-0.5532-0.55320.03160.14960.0823--4.6044,546.79-141.40-43.18-187.08-50.38-----1,717.50-279.82---178.630.0532---18.7151.13-18.19--22.97--
Aqua Bio Technology ASA152.67k-2.15m12.95m2.00--17.98--84.79-1.13-1.130.08040.36770.06440.66061.50---90.75-73.71-152.91-100.31-117.42-41.86-1,408.30-2,046.060.3127-12.490.4955--250.98---33.32--56.78--
Proteome Sciences plc7.36m643.39k13.90m27.0022.65--12.691.890.00180.00180.0208-0.00860.65142.885.35237,148.105.70-7.87----56.2959.948.75-15.710.3692.761.28--7.9113.33-75.59--43.95--
Klaria Pharma Holding AB (publ)0.00-8.14m13.92m----2.09-----1.54-1.540.000.6230.00-------85.46-29.15-132.95-33.67-------2,713.74---16.670.0211-------4.07------
Genomtec SA8.53k-1.45m13.96m----26.02--1,636.37-0.816-0.8160.00480.27290.00554.700.049---92.64---120.72---2,125.67---16,943.29--1.53-54.690.2992--993.80--51.80------
Data as of Dec 06 2022. Currency figures normalised to Addex Therapeutics Ltd's reporting currency: Swiss Franc CHF

Institutional shareholders

5.37%Per cent of shares held by top holders
HolderShares% Held
Caxton Corp.as of 31 Dec 20212.31m3.55%
Credit Suisse Asset Management (Schweiz) AGas of 23 Sep 20211.21m1.05%
Herculis Partners SAas of 31 Jan 2020405.14k0.35%
UBS Asset Management Switzerland AGas of 01 Nov 2022233.25k0.20%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020110.14k0.10%
Pictet Asset Management SAas of 31 Aug 202245.82k0.04%
BlackRock Asset Management Schweiz AGas of 03 Nov 202244.78k0.04%
Sectoral Asset Management, Inc.as of 31 Jul 201820.90k0.02%
Lombard Odier Asset Management (Switzerland) SAas of 31 Aug 202217.69k0.02%
DWS CH AGas of 30 Nov 202017.19k0.02%
More ▼
Data from 30 Sep 2022 - 31 Oct 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.